Leadership changes
Executive appointments and departures from SEC 8-K filings, updated within hours of each filing.
Updated Nov 10, 2026
Changes, November 2026
429
Appointments
211
Departures
45
Browse by role
Get new CFO appointments the day the filing lands.
Browse by month
Filters
3,854 changes
| Filing date | Company | Person | Role | Change | Effective date | Source |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | Supernus, Inc. | Jonathan Rubin | Senior Vice President, Chief Medical Officer, Research and DevelopmentCMO | Appointed | n/a | SEC 8-K |
| Nov 2, 2026 | Supernus, Inc. | Joseph Ciaffoni | directordirector | Departed | n/a | SEC 8-K |
| Nov 2, 2026 | Supernus, Inc. | David Wheadon | directordirector | Departed | n/a | SEC 8-K |
| Nov 2, 2026 | Supernus, Inc. | Daniel Ninivaggi | directordirector | Departed | n/a | SEC 8-K |
| Nov 2, 2026 | Supernus, Inc. | Georges Gemayel | directordirector | Appointed | n/a | SEC 8-K |
| Nov 2, 2026 | Supernus, Inc. | Carrolee Barlow | directordirector | Appointed | n/a | SEC 8-K |
| Nov 2, 2026 | Supernus, Inc. | Bethany Sensenig | directordirector | Appointed | n/a | SEC 8-K |
| Nov 2, 2026 | Supernus, Inc. | Tony Kingsley | Chair of the BoardChair of the Board | Appointed | n/a | SEC 8-K |
| Nov 2, 2026 | Syndax Pharmaceuticals Inc | Keith A. Goldan | Chief Financial OfficerCFO | Departed | Nov 9, 2026 | SEC 8-K |
| Nov 2, 2026 | Syndax Pharmaceuticals Inc | Aaron A. Ondrey | Chief Financial OfficerCFO | Appointed | Nov 9, 2026 | SEC 8-K |
| Nov 2, 2026 | Syndax Pharmaceuticals Inc | Aaron A. Ondrey | principal accounting and financial officerprincipal accounting and financial officer | Appointed | n/a | SEC 8-K |
| Nov 2, 2026 | TE Connectivity plc | Jennifer A. Johnson | Executive Vice President and Chief Legal OfficerCLO | Appointed | Nov 9, 2026 | SEC 8-K |
| Nov 2, 2026 | TE Connectivity plc | John S. Jenkins, Jr. | Executive Vice President and General CounselExecutive Vice President and General Counsel | Departed | Nov 9, 2026 | SEC 8-K |
| Nov 2, 2026 | TELOS CORP | Mark D. Griffin | President and Chief Executive OfficerCEO | Appointed | Nov 2, 2026 | SEC 8-K |
| Nov 2, 2026 | UPWORK, INC | Erica Gessert | Chief Financial Officer and principal financial officerCFO | Departed | Jan 1, 2027 | SEC 8-K |
| Nov 2, 2026 | UPWORK, INC | Peter Sanborn | Chief Financial Officer and principal financial officerCFO | Appointed | Jan 1, 2027 | SEC 8-K |
| Nov 2, 2026 | UR-ENERGY INC | Roger L. Smith | Chief Financial OfficerCFO | Departed | Dec 1, 2026 | SEC 8-K |
| Nov 2, 2026 | UR-ENERGY INC | Jade Walle | Chief Financial OfficerCFO | Appointed | Dec 1, 2026 | SEC 8-K |
| Nov 2, 2026 | Valion Bio, Inc. | Melinda Lackey | General Counsel and Senior Vice President of Legal AffairsCLO | Departed | Oct 30, 2026 | SEC 8-K |
| Nov 2, 2026 | Xeris Biopharma Holdings, Inc. | Menassie Taddese | Class II directorClass II director | Appointed | Nov 2, 2026 | SEC 8-K |
- Supernus, Inc.Appointed
Jonathan Rubin CMO
Filed Nov 2, 2026SEC 8-K
- Supernus, Inc.Departed
Joseph Ciaffoni director
Filed Nov 2, 2026SEC 8-K
- Supernus, Inc.Departed
David Wheadon director
Filed Nov 2, 2026SEC 8-K
- Supernus, Inc.Departed
Daniel Ninivaggi director
Filed Nov 2, 2026SEC 8-K
- Supernus, Inc.Appointed
Georges Gemayel director
Filed Nov 2, 2026SEC 8-K
- Supernus, Inc.Appointed
Carrolee Barlow director
Filed Nov 2, 2026SEC 8-K
- Supernus, Inc.Appointed
Bethany Sensenig director
Filed Nov 2, 2026SEC 8-K
- Supernus, Inc.Appointed
Tony Kingsley Chair of the Board
Filed Nov 2, 2026SEC 8-K
- Syndax Pharmaceuticals IncDeparted
Keith A. Goldan CFO
Filed Nov 2, 2026Effective Nov 9, 2026SEC 8-K
- Syndax Pharmaceuticals IncAppointed
Aaron A. Ondrey CFO
Filed Nov 2, 2026Effective Nov 9, 2026SEC 8-K
- Syndax Pharmaceuticals IncAppointed
Aaron A. Ondrey principal accounting and financial officer
Filed Nov 2, 2026SEC 8-K
- TE Connectivity plcAppointed
Jennifer A. Johnson CLO
Filed Nov 2, 2026Effective Nov 9, 2026SEC 8-K
- TE Connectivity plcDeparted
John S. Jenkins, Jr. Executive Vice President and General Counsel
Filed Nov 2, 2026Effective Nov 9, 2026SEC 8-K
- TELOS CORPAppointed
Mark D. Griffin CEO
Filed Nov 2, 2026Effective Nov 2, 2026SEC 8-K
- UPWORK, INCDeparted
Erica Gessert CFO
Filed Nov 2, 2026Effective Jan 1, 2027SEC 8-K
- UPWORK, INCAppointed
Peter Sanborn CFO
Filed Nov 2, 2026Effective Jan 1, 2027SEC 8-K
- UR-ENERGY INCDeparted
Roger L. Smith CFO
Filed Nov 2, 2026Effective Dec 1, 2026SEC 8-K
- UR-ENERGY INCAppointed
Jade Walle CFO
Filed Nov 2, 2026Effective Dec 1, 2026SEC 8-K
- Valion Bio, Inc.Departed
Melinda Lackey CLO
Filed Nov 2, 2026Effective Oct 30, 2026SEC 8-K
- Xeris Biopharma Holdings, Inc.Appointed
Menassie Taddese Class II director
Filed Nov 2, 2026Effective Nov 2, 2026SEC 8-K